EP3468965B1 - 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer - Google Patents

1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer Download PDF

Info

Publication number
EP3468965B1
EP3468965B1 EP17728990.7A EP17728990A EP3468965B1 EP 3468965 B1 EP3468965 B1 EP 3468965B1 EP 17728990 A EP17728990 A EP 17728990A EP 3468965 B1 EP3468965 B1 EP 3468965B1
Authority
EP
European Patent Office
Prior art keywords
cancer
dihydro
compound
indol
pyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP17728990.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3468965A1 (en
Inventor
Jolie Anne Bastian
Jiehao Chen
Jeffrey Daniel Cohen
James Robert Henry
William Thomas Mcmillen
Bradley Earl REAMAN
Almudena RUBIO
Daniel Jon Sall
Gaiying ZHAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to MEP-2020-98A priority Critical patent/ME03744B/me
Priority to SI201730252T priority patent/SI3468965T1/sl
Priority to PL17728990T priority patent/PL3468965T3/pl
Priority to RS20200623A priority patent/RS60322B1/sr
Publication of EP3468965A1 publication Critical patent/EP3468965A1/en
Application granted granted Critical
Publication of EP3468965B1 publication Critical patent/EP3468965B1/en
Priority to HRP20200769TT priority patent/HRP20200769T1/hr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings

Definitions

  • the present invention relates to novel 2,3-dihydro-1H-indole compounds that inhibit the conversion of tryptophan to kynurenine, certain of which have been confirmed to bind to indoleamine 2,3-dioxygenase (IDO1).
  • the present invention also relates to pharmaceutical compositions comprising these compounds and methods of using these compounds to treat physiological disorders, more particularly for the treatment of cancer such as melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, renal cell carcinoma, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
  • cancer such as melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, renal cell carcinoma, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
  • Tryptophan is an essential amino acid required for protein biosynthesis, cellular growth, the generation of neuroactive metabolites such as serotonin (5-hydroxytryptamine), melatonin, and the co-enzyme nicotinamide adenine dinucleotide (NAD). Tryptophan is catabolized by indoleamine 2,3-dioxygenase (IDO1), a heme-dependent enzyme that catalyzes the first and rate-limiting step in tryptophan catabolism to N-formyl-kynurenine, which is then deformylated to generate kynurenine.
  • IDO1 indoleamine 2,3-dioxygenase
  • IDO1 During infection, the expression of IDO1 is induced by interferon gamma to locally deplete tryptophan, which inhibits the growth of tryptophan-dependent intracellular pathogens such as Chlamydia trachomatis, Toxoplasma gondii, and viruses. Additionally, IDOl plays a role in preventing oxidative damage in cells, several neuropathologies, regulation of the immune system, and cancer. Although IDOl activity is a critical component of the immune response to pathogens, prolonged activity results in the depletion of extracellular tryptophan with the concomitant production of kynurenine, both of which are immunosuppressive.
  • IDO1 expression in cancer is well documented and occurs through both intrinsic activation of IDO1 gene expression and/or through the activation of the IFN- ⁇ -to-IDO1 axis, a result of immune cell activation. Additionally, innate immune cells such as dendritic cells, monocytes and macrophages, which are recruited to sites of inflammation and the tumor microenvironment, are immunosuppressive when they express IDO1. Together the IDO1-dependent depletion of tryptophan and production of kynurenine have been linked to suppression of T-cell activation and proliferation and NK cell function.
  • Treg regulatory T cells
  • MDSCs myeloid-derived suppressor cells
  • such compounds would also be orally bioavailable.
  • such compounds would also have the ability to cross the blood brain barrier and thus have brain exposure.
  • such compounds would also have the ability to potentially overcome resistance to existing kynurenine inhibitors by having an alternate mechanism of action.
  • the present invention provides certain novel 2,3-dihydro-1H-indole compounds that are inhibitors of kynurenine production.
  • inhibitors of kynurenine production may have clinical utility as a single agent or in combination with other anti-cancer agents for the treatment of different types of cancers and in particular melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, renal cell carcinoma, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
  • the present invention also provides a compound of the formula: wherein:
  • the present invention provides a compound of the formula:
  • the present invention also provides a compound of the formula:
  • the present invention also provides a compound of the formula:
  • the present invention also provides a compound which is 4-fluoro-N- ⁇ (1R)-1-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-2,3-dihydro-1H-indol-5-yl]ethyl ⁇ benzamide.
  • the compound is 4-fluoro-N- ⁇ (1R)-1-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-2,3-dihydro-1H-indol-5-yl]ethyl ⁇ benzamide in a crystalline form.
  • the compound is crystalline 4-fluoro-N- ⁇ (1R)-1-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-2,3-dihydro-1H-indol-5-yl]ethyl ⁇ benzamide characterized by an X-ray powder diffraction pattern (Cu radiation, ⁇ -1.54060 ⁇ ) comprising at least one peak at 17.38° in combination with one or more peaks selected from the group consisting of 12.51°, 15.65°, 16.37°, 17.56°, 21.48° and 25.23° (2 ⁇ 0.2°).
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the present invention with a pharmaceutically acceptable excipient, carrier, or diluent.
  • the compound is 4-fluoro-N- ⁇ (1R)-1-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-2,3-dihydro-1H-indol-5-yl]ethyl ⁇ benzamide.
  • the present invention provides a method of treating a patient with a cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, renal cell carcinoma, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma comprising administering to the patient an effective amount of a compound of the present invention.
  • the cancer is melanoma.
  • the cancer is colorectal cancer.
  • the cancer is renal cell carcinoma.
  • the cancer is breast cancer.
  • the cancer is lung cancer, in particular non-small cell lung cancer.
  • the cancer is ovarian cancer.
  • the cancer is glioma.
  • the compound is 4-fluoro-N- ⁇ (1R)-1-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-2,3-dihydro-1H-indol-5-yl]ethyl ⁇ benzamide.
  • This invention also provides a compound of the present invention for use in therapy. Additionally, this invention provides a compound of the present invention for use in the treatment of a cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, renal cell carcinoma, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
  • a cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, renal cell carcinoma, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymph
  • the cancer is renal cell carcinoma, Preferably the cancer is breast cancer.
  • the cancer is lung cancer, in particular non-small cell lung cancer.
  • the cancer is ovarian cancer.
  • the cancer is glioma.
  • the compound is 4-fluoro-N- ⁇ (1R)-1-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-2,3-dihydro-1H-indol-5-yl]ethyl ⁇ benzamide.
  • the compound is 4-fluoro-N- ⁇ (1R)-1-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-2,3-dihydro-1H-indol-5-yl]ethyl ⁇ benzamide.
  • This invention also provides a combination comprising a compound of the present invention and LY3300054 for simultaneous, separate, or sequential use in the treatment of a cancer selected from the group consisting of non-small cell lung cancer and colon cancer.
  • a cancer selected from the group consisting of non-small cell lung cancer and colon cancer.
  • the cancer is non-small cell lung cancer.
  • the cancer is colon cancer.
  • the compound is 4-fluoro-N- ⁇ (1R)-1-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-2,3-dihydro-1H-indol-5-yl]ethyl ⁇ benzamide.
  • the compound is 4-fluoro-N- ⁇ (1R)-1-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-2,3-dihydro-1H-indol-5-yl]ethyl ⁇ benzamide and the cancer is non-small cell lung cancer.
  • the compound is 4-fluoro-N- ⁇ (1R)-1-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-2,3-dihydro-1H-indol-5-yl]ethyl ⁇ benzamide and the cancer is colon cancer.
  • Certain of the compounds of the present invention are crystalline. It is well known in the crystallography art that, for any given crystal form, the relative intensities of the diffraction peaks may vary due to preferred orientation resulting from factors such as crystal morphology and habit. Where the effects of preferred orientation are present, peak intensities are altered, but the characteristic peak positions of the polymorph are unchanged. See, e.g. The U. S. Pharmacopeia 38 - National Formulary 35 Chapter ⁇ 941> Characterization of crystalline and partially crystalline solids by X-ray powder diffraction (XRPD) Official May 1, 2015 . Furthermore, it is also well known in the crystallography art that for any given crystal form the angular peak positions may vary slightly.
  • peak positions can shift due to a variation in the temperature or humidity at which a sample is analyzed, sample displacement, or the presence or absence of an internal standard.
  • a peak position variability of ⁇ 0.2 in 2 ⁇ will take into account these potential variations without hindering the unequivocal identification of the indicated crystal form.
  • Confirmation of a crystal form may be made based on any unique combination of distinguishing peaks (in units of ° 2 ⁇ ), typically the more prominent peaks.
  • the crystal form diffraction patterns, collected at ambient temperature and relative humidity, were adjusted based on NIST 675 standard peaks at 8.85 and 26.77 degrees 2-theta.
  • treat refers to restraining, slowing, stopping, or reversing the progression or severity of an existing symptom or disorder.
  • the term "patient” refers to a warm blooded animal such as a mammal, in particular a human, which is afflicted with a particular disease, disorder, or condition.
  • Some intermediates or compounds of the present invention disclosed herein may have one or more chiral or stereogenic centers. All individual stereoisomers, enantiomers and diastereomers, as well as mixtures of the enantiomers and diastereomers of all of these aforementioned compounds or intermediates of the present invention are contemplated including racemates. It is preferred that compounds or intermediates of the present invention disclosed herein containing at least one chiral center exist as single enantiomers or diastereomers. The single enantiomer or diastereomer may be prepared beginning with chiral reagents or by stereoselective or stereospecific synthetic techniques (as illustrated in the preparations and examples).
  • the single enantiomer or diastereomers may be isolated from mixtures by standard chiral chromatographic (as illustrated in the preparations and examples) or crystallization techniques.
  • standard chiral chromatographic as illustrated in the preparations and examples
  • crystallization techniques crystallization techniques
  • the designation of "Isomer 1" in a compound name represents that the corresponding intermediate or compound of the present invention is the first of two eluting enantiomers when a mixture of a pair of enantiomers is separated by chiral chromatography.
  • the designation of "Isomer 2" in a compound name represents that the corresponding intermediate or compound of the present invention is the second of two eluting enantiomers when the mixture of a pair of enantiomers is separated by chiral chromatography.
  • LY3300054 is an antibody that binds human PD-L1 (SEQ ID NO: 1), comprising a light chain (LC) and a heavy chain (HC), wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), and wherein the LCVR comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, where the amino acid sequence of LCDR1 is SGSSSNIGSNTVN (SEQ ID NO: 5), the amino acid sequence of LCDR2 is YGNSNRPS (SEQ ID NO: 6), and the amino acid sequence of LCDR3 is QSYDSSLSGSV (SEQ ID NO: 7), and wherein the HCVR comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, where the amino acid sequence of HCDR1 is KASGGTFSSYAIS (SEQ ID NO: 2), the amino acid sequence of HCDR2 is GIIPIFGTANYAQKF
  • the LY3300054 binds to human PD-L1, and comprises a light chain (LC) and a heavy chain (HC), wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), wherein the amino acid sequence of the LCVR is SEQ ID NO: 9, and the amino acid sequence of the HCVR is SEQ ID NO: 8.
  • the LY3300054 binds to human PD-L1, comprising a light chain (LC) and a heavy chain (HC), wherein the amino acid sequence of the LC is SEQ ID NO: 10 and the HC has the amino acid sequence given in SEQ ID NO: 11.
  • the LY3300054 comprises two light chains and two heavy chains, wherein each light chain has the amino acid sequence given in SEQ ID NO: 11, and each heavy chain has the amino acid sequence given in SEQ ID NO: 10.
  • LCVR light chain variable region
  • HCVR heavy chain variable region
  • the terms "complementarity determining region” and "CDR”, mean the non-contiguous antigen combining sites found within the variable region of LC and HC polypeptides of an antibody or an antigen-binding fragment thereof. These particular regions have been described by others including Kabat, et al., Ann. NY Acad. Sci. 190:382-93 (1971 ); Kabat et al., J. Biol. Chem. 252:6609-6616 (1977 ); Kabat, et al., Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242 (1991 ); Chothia, et al., J. Mol.
  • Each LCVR and HCVR is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • the three CDRs of the light chain are referred to as "LCDR1, LCDR2, and LCDR3" and the three CDRs of the heavy chain are referred to as "HCDR1, HCDR2, and HCDR3.”
  • the CDRs contain most of the residues which form specific interactions with the antigen.
  • the numbering and positioning of CDR amino acid residues within the LCVR and HCVR regions is in accordance with known conventions (e.g., Kabat (1991), Chothia (1987), and/or North (2011)).
  • the FRs of the LY3300054 may be identical to the human germline sequences, or may be naturally or artificially modified.
  • K D means the equilibrium dissociation constant of a particular antibody-antigen or antibody fragment-antigen interaction.
  • the term "binds" means the affinity of an antibody for human PD-L1 is intended to mean, unless indicated otherwise, a K D of less than about 1 x10 -6 M, preferably, less than about 1 x 10 -9 M as determined by common methods known in the art, including by use of a surface plasmon resonance (SPR) biosensor at 37 °C essentially as described herein.
  • SPR surface plasmon resonance
  • ACN refers to acetonitrile
  • APCI atmospheric pressure chemical ionization
  • BTI refers to [bis(trifluoroacetoxy)iodo]benzene
  • CDI carbonyldiimidazole
  • DCM dichloromethane
  • DMSO dimethyl sulfoxide
  • DMF dimethyl sulfoxide
  • DPBS Dulbecco's phosphate-buffered saline
  • ES refers to electrospray ionization
  • EtOAc refers to ethyl acetate
  • EtOH refers to ethanol
  • FBS refers to fetal bovine serum
  • HPLC refers to high performance liquid chromatography
  • iPrOH refers to isopropanol
  • LC/MS-MS refers to LC/MS-MS
  • the compounds of the present invention can be prepared according to the following schemes, preparations and examples by methods well known and appreciated in the art. Suitable reaction conditions for the steps of these preparations and examples are well known in the art and appropriate substitutions of solvents and co-reagents are within the skill of the art. Likewise, it will be appreciated by those skilled in the art that synthetic intermediates may be isolated and/or purified by various well known techniques as needed or desired, and that frequently, it will be possible to use various intermediates directly in subsequent synthetic steps with little or no purification. Furthermore, the skilled artisan will appreciate that in some circumstances, the order in which moieties are introduced is not critical.
  • Scheme 1 illustrates the general synthesis of compounds of Formula I, R2 is H.
  • a 2,3-dihydro-1H-indole (Compound 1) is reacted with an appropriate activated carboxylic acid such as an acid chloride in the presence of a suitable base such as TEA and in a suitable solvent such as DCM or dichloroethane (DCE) at an appropriate temperature such as 0 °C to refluxing.
  • a suitable base such as TEA
  • DCM or dichloroethane (DCE) dichloroethane
  • Step 2 The resulting ketone (Compound 2) of Step 1 is then treated with hydroxylamine in a polar protic solvent such as EtOH at an appropriate temperature such as room temperature to refluxing to give the oxime as a mixture of E and Z isomers (Compound 3).
  • Step 3 shows the reduction of the oxime (Compound 3) to the amine (Compound 4).
  • an appropriate catalyst such as RANEY® nickel in an appropriate solvent such as MeOH or EtOH in an appropriate reactor such as a PARR® shaker.
  • Scheme 1, Step 4 depicts the amide coupling of the amine (Compound 4) with an appropriate activated carboxylic acid such as an acid chloride in the presence of a suitable base such as TEA and in a suitable solvent such as DCM or DCE at an appropriate temperature such as 0 °C to refluxing to give a compound of Formula I.
  • a suitable base such as TEA
  • DCM or DCE at an appropriate temperature such as 0 °C to refluxing to give a compound of Formula I.
  • a skilled artisan will appreciate that there are many activated carboxylic acids and many methods to activate carboxylic acids in situ to accomplish the reaction of Step 4. The skilled artisan will further appreciate that Scheme 1, Step 3 and Step 4 result in products with chiral centers.
  • Scheme 2 illustrates an alternate general synthesis of compounds of Formula I, R2 is H.
  • Step 1 the ketone (Compound 2) is reacted with an appropriate chiral sulfinamide in the presence of an appropriate Lewis acid such as titanium(IV) ethoxide in an appropriate solvent such as THF at an appropriate temperature such as room temperature to reflux for an appropriate time such as one to 24 hours to give a chiral ethylidenesulfinamide (Compound 5).
  • an appropriate Lewis acid such as titanium(IV) ethoxide
  • THF an appropriate solvent
  • a skilled artisan will appreciate that reagents are available to generate either enantiomer of the sulfinamide (Compound 5).
  • Step 2 Chiral reduction is depicted in Step 2 to generate an ethylsulfinamide (Compound 6) from an ethylidinesulfinamide (Compound 5) and asterisks are used to indicate chiral centers for clarity.
  • an appropriate catalyst is pre-formed by mixing an appropriate ruthenium reagent such as dichloro(p-cymene)ruthenium(II) dimer with an appropriate aminoethanol such as 2-amino-2-methyl-1-propanol in an appropriate solvent such as iPrOH in the presence of a water scavenger such as 4 ⁇ molecular sieves at an appropriate temperature such as room temperature to refluxing for an appropriate time such as five minutes to approximately one hour.
  • an appropriate ruthenium reagent such as dichloro(p-cymene)ruthenium(II) dimer
  • an appropriate aminoethanol such as 2-amino-2-methyl-1-propanol
  • an appropriate solvent such as iPrOH
  • the preformed catalyst reaction is cooled to an appropriate temperature such as room temperature to 50 °C and treated with an ethylidenesulfinamide (Compound 5) and an appropriate base such as potassium tert-butoxide.
  • the reaction is maintained at an appropriate temperature such as room temperature to 50 °C for an appropriate time such as one to 24 hours.
  • an appropriate temperature such as room temperature to 50 °C
  • an appropriate time such as one to 24 hours.
  • Acid hydrolysis of a ethylsulfinamide can be affected by treatment with an appropriate acid such as hydrochloric acid (HCl) in an appropriate solvent such as dioxane, iPrOH, EtOAc or MeOH at an appropriate temperature such as 0 °C to room temperature for an appropriate time such as one to eight hours to give an amine (Compound 4).
  • an appropriate acid such as hydrochloric acid (HCl) in an appropriate solvent such as dioxane, iPrOH, EtOAc or MeOH
  • HCl hydrochloric acid
  • EtOAc EtOAc
  • MeOH a solvent
  • Step 4 depicts the amide coupling of an amine (Compound 4) with an appropriate activated carboxylic acid analogous to Scheme 1, Step 4 above to give a compound of Formula I.
  • Scheme 3 depicts an alternate general synthesis of a compound of Formula I, R2 is H.
  • Step 1 depicts an amide coupling of a carboxylic acid (Compound 7) with N,O-dimethylhydroxylamine hydrochloride to give a Weinreb amide (Compound 8).
  • Compound 7 depicts an amide coupling of a carboxylic acid (Compound 7) with N,O-dimethylhydroxylamine hydrochloride to give a Weinreb amide (Compound 8).
  • a carboxylic acid (Compound 7) can be treated with an appropriate coupling reagent such as 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxid hexafluorophosphate (HATU) in the presence of an appropriate base such as N,N-diisopropylethylamine in an appropriate solvent such as DMF for an appropriate time such as five to ten minutes.
  • HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxid hexafluorophosphate
  • an appropriate base such as N,N-diisopropylethylamine
  • an appropriate solvent such as DMF
  • the mixture is then treated with N,O-dimethylhyrdoxylamine hydrochloride and the mixture is stirred at an appropriate temperature such as room temperature to 100 °C for an appropriate time such as three to 18
  • the resulting Weinreb amide (Compound 8) is then treated with an appropriate Grignard, alkyl lithium or alkyl zinc reagent, in Step 2, to give a ketone (Compound 9).
  • an appropriate Grignard, alkyl lithium or alkyl zinc reagent in Step 2, to give a ketone (Compound 9).
  • the Weinreb amide (Compound 8) in an appropriate solvent such as THF at an appropriate temperature such as 0 °C to -78 °C is treated with an appropriate alkyl metal reagent such as ethylmagnesium bromide.
  • the reaction is continued after the addition for an appropriate time such as one to 18 hours to give a ketone (Compound 9).
  • Steps 3, 4 and 5 of Scheme 3 are presented for clarity.
  • Step 6 depicts the deprotection of the tert-butoxycarbonyl protecting group of a carbamate (Compound 12) to give an amine (Compound 13).
  • This transformation can be conducted under acid, base or thermal conditions.
  • a carbamate (Compound 12) is contacted with an appropriate acid such as HCl in an appropriate solvent such as dioxane or DCM or a mixture thereof at an appropriate temperature such as 0 °C to refluxing for an appropriate time such as one to 18 hours to give an amine (Compound 13).
  • an appropriate acid such as HCl
  • an appropriate solvent such as dioxane or DCM or a mixture thereof
  • an appropriate temperature such as 0 °C to refluxing for an appropriate time such as one to 18 hours
  • Step 7 depicts the amide coupling of an amine (Compound 13) and an activated carboxylic acid to give a compound of Formula I.
  • the conditions are analogous to those presented in Scheme 1, Step 1.
  • Scheme 4 depicts an alternate general synthesis of a compound of Formula I.
  • Step 1 depicts the protection of an amine (Compound 11) with a benzyl carbamate protecting group to give a carbamate (Compound 14).
  • a skilled artisan will appreciate that there are many amine protecting groups available that would be orthogonal protecting groups to the tert-butoxycarbonyl group on compound 14.
  • an amine (Compound 11) in an appropriate solvent such as DCM and in the presence of a suitable base such as N,N-diisopropylethylamine is contacted with benzyloxychloroformate at an appropriate temperature such as 0 °C to room temperature for an appropriate time such as one to 18 hours.
  • the tert-butoxycarbonyl protecting group of Compound 14 is selectively deprotected to give an amine (Compound 15) utilizing methods analogous to those described for Scheme 3, Step 6.
  • the resulting amine (Compound 15) is then subjected to an amide coupling reaction with an activated carboxylic acid by methods analogous to those in Scheme 1, Step 1 to give an amide (Compound 16).
  • Step 4 depicts the deprotection of the benzyloxy carbamate protecting group of compound 16 to give an amine (Compound 4).
  • a skilled artisan will appreciate that a variety of methods are available to affect this transformation.
  • Scheme 5 depicts an alternate general synthesis of a compound of Formula I.
  • Step 1 depicts the amide coupling of an amine (Compound 17) and an activated carboxylic acid to give an amide (Compound 18).
  • the conditions are analogous to those presented in Scheme 1, Step 1.
  • Step 2 depicts the formation of alpha aryl ester (Compound 19) through the catalytic cross coupling of a bromide (Compound 18) with an ester enolate.
  • the skilled artisan will appreciate the wide range of conditions that can affect this transformation.
  • a solution of an appropriate dialkyl amine such as dicyclohexylamine in an appropriate solvent such as toluene is treated with an appropriate lithium base such as n-butyllithium at an appropriate temperature such as 0 °C to -78 °C for an appropriate time such as 10 minutes to one hour.
  • This solution is treated with a solution of an appropriate ester such as methyl 2-methylpropanoate in an appropriate solvent such as toluene and the resulting mixture is stirred for an appropriate time such as 10 minutes to one hour at an appropriate temperature such as 0 °C to -40 °C.
  • an appropriate palladium catalyst such as di- ⁇ -bromobis(tri-t-butylphosphine)dipalladium(I) and the mixture is stirred at an appropriate temperature such as 0 °C to room temperature for an appropriate time such as one to 18 hours to give an alpha aryl ester (Compound 19).
  • An ester (Compound 19) can be hydrolyzed to an acid (Compound 20) by methods well known in the art. For example, an ester (Compound 19) is contacted with a suitable base such as potassium trimethylsilanolate in an appropriate solvent such as THF at an appropriate temperature such as room temperature to refluxing for an appropriate time such as one to seven days.
  • Step 4 depicts the amide coupling of a carboxylic acid (Compound 20) with ammonia to give a carboxamide (Compound 21).
  • a carboxylic acid Compound 20
  • a carboxylic acid Compound 20
  • 1,1'-carbonyldiimidazole in an appropriate solvent such as DCM or DMF or a mixture thereof at an appropriate temperature such as 0 °C to refluxing for an appropriate time such as 30 minutes to eight hours.
  • Ammonium hydroxide is added to the mixture and the reaction is continued for an additional time such as one to 18 hours.
  • Step 21 depicts the Hoffman rearrangement of a carboxamide (Compound 21) to an amine (Compound 4).
  • a carboxamide (Compound 21) in an appropriate solvent such as a mixture of ACN and water is treated with [bis(trifluoroacetoxy)iodo]benzene at appropriate temperature such as room temperature to refluxing for an appropriate time such as one to 18 hours.
  • an appropriate solvent such as a mixture of ACN and water
  • [bis(trifluoroacetoxy)iodo]benzene at appropriate temperature such as room temperature to refluxing for an appropriate time such as one to 18 hours.
  • the conversion of amine (Compound 4) to a compound of Formula I is describe in Scheme 1, Step 4.
  • the sample is scanned between 4 and 40° in 2 ⁇ , with a step size of 0.0087° in 2 ⁇ and a scan rate of 0.5 seconds/step, and with 0.6 mm divergence, 5.28mm fixed anti-scatter, and 9.5 mm detector slits.
  • the dry powder is packed on a quartz sample holder and a smooth surface is obtained using a glass slide. Collect the crystal form diffraction patterns at ambient temperature and relative humidity.
  • Example 1A is characterized by an XRD pattern using CuKa radiation as having diffraction peaks (2-theta values) as described in Table 1 below. Specifically the pattern contains a peak at 17.38° in combination with one or more of the peaks selected from the group consisting of 12.51°, 15.65°, 16.37°, 17.56°, 21.48° and 25.23° with a tolerance for the diffraction angles of 0.2 degrees (2 ⁇ 0.2°). Table 1.
  • the calculated density is 1.319 g/cm 3 and F(000), 420 e-.
  • the absolute structure parameter refines to 0.12(16), verifying the stereochemistry of the chiral center.
  • the absolute structure is determined to be the R- configuration at the stereocenter.
  • Example 2 essentially analogous to Example 1, using the starting material from Preparation 3.
  • Example 3 essentially analogous to Example 1, using the starting material from Preparation 3.
  • Example 3 essentially analogous to Example 1, using the starting material from Preparation 3.
  • Example 3 essentially analogous to Example 1, using the starting material from Preparation 3.
  • Example 3 essentially analogous to Example 1, using the starting material from Preparation 3.
  • Example 3 essentially analogous to Example 1, using the starting material from Preparation 3.
  • Chemical Name Structure Physical data 2 Racemic 4-chloro-N- ⁇ 1-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-2,3-dihydro-1H-indol-5-yl]ethyl ⁇ benzamide ES/MS (m/z): 413.0 (M+H)
  • the immune system is a critical checkpoint that restrains tumor development.
  • cancers have evolved many mechanisms to evade, suppress, or otherwise subvert the immune system.
  • tryptophan is absolutely essential for cancer cell growth, its degradation is selected for in a broad array of cancers through the expression of indoleamine 2,3 dioxygenase (IDO1) either by the cancer cell itself (intrinsic), or by cells in the microenvironment or tumor draining lymph nodes (TDLNs) (extrinsic).
  • IDO1 indoleamine 2,3 dioxygenase
  • TDLNs tumor draining lymph nodes
  • the selective activation of IDOl in the tumor microenvironment while counter to rapid cell growth provides the tumor with an effective strategy to avoid immunosurveillance, a critical checkpoint in cancer development and resistance to therapy.
  • the immunosuppressive activity of IDOl is a direct result of the local depletion of tryptophan and the concomitant production of kynurenine, both of which are
  • the immunosuppressive role of IDOl activity impacts multiple cell types including cell suppression [T-cells ( Frumento, et al. (2002) J Exp Med 196(4): 459-468 ; Terness, et al. (2002) J Exp Med 196(4): 447-457 ) and NK cells ( Della Chiesa, et al. (2006) Blood 108(13): 4118-4125 )], cell development [regulatory T-cells ( Sharma, et al. (2007) J Clin Invest 117(9): 2570-2582 ; Chen, et al. (2008) J Immunol 181(8): 5396-5404 ; Baban, et al.
  • T-cells lacking GCN2 are not susceptible to IDO1-mediated inhibition of proliferation or the induction of an anergic phenotype ( Munn, et al. (2005) Immunity 22(5): 633-642 ).
  • IDOl activity leads to high concentrations of the downstream metabolite kynurenine, an important immunosuppressive molecule.
  • AHR aryl hydrocarbon receptor
  • IDOl-mediated IL-6 production also plays an important role in supporting the development of pro-tumorigenic MDSCs and disruption of IDOl reduced IL-6 production, attenuated MDSC suppressive activity, delayed tumor growth and increased survival in a KRAS-induced lung cancer model ( Smith, et al. (2012) Cancer Discov 2(8): 722-735 ).
  • the connection between IDOl-dependent depletion of tryptophan and kynurenine-dependent activation of AHR provides a lynch pin explaining why tryptophan catabolism is intimately associated with immune escape, a critical checkpoint that restrains cancer progression.
  • IDOl The regulation of IDOl expression in the tumor microenvironment is complex. IDOl was the first IFN- ⁇ -regulated gene discovered ( Yoshida, et al. (1981) Proc Natl Acad Sci USA 78(1): 129-132 ). In fact, there is a strong correlation between IFN- ⁇ and IDOl expression across all cancer histologies (http://cancergenome.nih.gov/). Additionally, IDOl expression is upregulated by type I interferons, TLR ligands, TNF, IL-1, CTLA-4, CD200, GITR, CD40 and TGF- ⁇ , all of which play important roles in the immune system, and cancer development, progression and response to therapy.
  • IFN- ⁇ is a critical effector cytokine secreted from activated NK and T-cells.
  • Negative regulatory circuits that are engaged to restrain T-cell activity either systemically (CTLA-4) or locally (PD-L1/L2) are currently approved for use as anti-cancer agents where they enhance T-cell-mediated tumor growth inhibition.
  • Genetic knockouts of checkpoints such as CTLA-4, PD-1 or PD-L1 result in the marked enhancement of IFN- ⁇ production ( Latchman, et al. (2004) Proc Natl Acad Sci USA 101(29): 10691-10696 ; Pandiyan, et al. (2007) J Immunol 178(4): 2132-2140 ), which can engage the immunosuppressive IFN- ⁇ -to-IDO1 axis.
  • IDOl was shown to impede the efficacy of these checkpoint inhibitors through the induction of Tregs with the subsequent recruitment of MDSCs creating an immunosuppressive environment at the tumor ( Holmgaard, et al. (2015) Cell Rep 13(2): 412-424 ).
  • Immunotherapeutic approaches to treat cancer such as IFN- ⁇ itself, innate immune activators such as CpG-ODNs, anti-4-1BB (CD137), anti-OX40, anti-PD-1/PD-L1/PD-L2, anti-CTLA 4 all have the potential to activate IDOl expression restraining their long-term efficacy in the clinic. Therefore, there may be significant therapeutic potential in combining IDOl inhibitors with these agents.
  • IDOl inhibitors with anti-PDl antibodies (pidilizumab, nivolumab, pembrolizumab), anti-PD-L1 antibodies (durvalumab, atezolizumab, avelumab), anti-CTLA-4 antibodies (ipilimumab), anti-OX40 antibodies (MEDI6469, KHK4083) and anti-4-1BB (CD137) antibodies (PF-05082566) have significant therapeutic potential in a wide range of tumor types.
  • IDO1 inhibitors inhibitors of tryptophan depletion and the concomitant production of kynurenine such as IDO1 inhibitors may be useful as a single agent or in combination in a variety of cancer types in both treatment naive as well as treatment resistant cancer patients.
  • IDOl inhibitors such as epacadostat (INCB024360) and NLG919.
  • Epacadostat is known to bind to IDOl and block the catabolism of tryptophan and the subsequent production of kynurenine both in vitro and in vivo.
  • epacadostat has demonstrated single agent efficacy in pre-clinical mouse models, CT26 and PAN02, an effect that is dependent upon the presence of T-cells.
  • the pre-clinical efficacy of epacadostat has translated into human clinical trial outcomes (NCT01195311).
  • results of the following assays demonstrate evidence that the compounds exemplified herein are useful as kynurenine production inhibitors such as IDOl inhibitors and may be useful in treating cancer. Furthermore, the results of the following assays demonstrate that certain exemplified compounds bind to IDO1 and that all exemplified compounds inhibit the conversion of tryptophan to kynurenine in cancer cells both in vitro and in vivo.
  • this assay assesses the ability of test compounds to compete with a tritiated spy molecule 1-(2,4-difluorophenyl)-3-[[1-(3,4,5-tritritiobenzoyl)indolin-5-yl]methyl]urea and allows for the calculation of the binding affinity, IC 50 .
  • the purpose of this assay is to evaluate the inhibition of the production of kynurenine, N-formyl-kynurenine and the depletion of tryptophan in IDOl expressing cancer cells and assess whether compounds are overtly toxic to these cells.
  • Exemplary compounds are tested for the inhibition of IDOl activity in SKOV3 (ATCC, Cat# HTB-77), an ovarian cancer cell line that intrinsically expresses IDO1. Due to IDOl expression, SKOV3 cells degrade tryptophan with the concomitant production of kynurenine and compounds are tested for their ability to inhibit the production of kynurenine, N-formyl-kynurenine and the depletion of tryptophan.
  • overt toxicity of compounds can be assessed by monitoring cell viability.
  • SKOV3 cells an IDO1-expressing ovarian cancer cell line, at 20,000 cells per well in 100 ⁇ L of McCoys 5A media (Gibco, Cat# 16600-082) supplemented with non-essential amino acids (Gibco, Cat# 11140-050), 1 mM sodium pyruvate (Gibco, Cat#11360-070), and 10% fetal bovine serum, complete media, in a 96 well tissue culture plate (BD Biosciences). Then, incubate cells for 16 hours in a 37 °C incubator with 5% CO 2 . Prepare compound serial dilutions from 10 mM stock test compounds in DMSO.
  • the final DMSO concentration in the assay is 0.5%.
  • the mobile phase A is 0.1% formic acid in water
  • mobile phase B is MeOH.
  • the gradient profile is: 0 minutes, 0.5% B; 0.8 minutes, 98% B; 1.10 minutes, 98% B; 1.11 minutes, 0.5% B; 1.7 minutes, and then stopped.
  • Operate the mass spectrometer in APCI positive multiple reaction monitoring mode. Use data from standard curve samples and generate a linear fit calibration curve for each analyte using the MultiQuanTM software. Use the standard curve generated to calculate the analyte concentrations for the unknowns.
  • the purpose of this assay is to evaluate the inhibition of kynurenine production and tryptophan depletion in cancer cells in vivo.
  • SKOV3X Indiana University Research and Technology Center
  • an ovarian cancer cell line intrinsically expresses IDOl and readily forms tumors in the peritoneal cavity of Athymic Nude-Foxn1 nu mice (Harlan).
  • IDOl expression SKOV3X tumors locally deplete tryptophan with the concomitant production of high levels of kynurenine in the tumor microenvironment.
  • the purpose of this assay is to measure the ability of test compounds to inhibit IDOl evidenced by the clear reduction in kynurenine levels in the tumor.
  • stripped matrices which are plasma and tissue homogenates depleted of L-kynurenine and L-tryptophan by dialysis. Then, fortify stripped matrices with known amounts of L-kynurenine and L-tryptophan.
  • Generate stripped mouse plasma by adding 10 mL of EDTA treated mouse plasma (BioreclamationIVT, Cat# MSEPLEDTA3) to a SPECTRA/POR® FLOAT-A-LYZER® G2 (Spectrum Labs, Cat# G235063) and placing this dialysis device in 1000 mL of phosphate buffered saline and dialyze overnight.
  • Mobile phase A is water/TFA/1 M ammonium bicarbonate, (1000:4:1, v/v/v) and mobile phase B is ACN/TFA/1 M ammonium bicarbonate 1000:4:1, v/v/v).
  • the gradient profile is: 0 minutes, 0.3% B; 0.03 to 0.2 minutes, 7% B; 0.3 to 0.4 minutes, 36% B; 0.41 minutes, 98% B, then stopped at 0.7 minutes to return to the original conditions.
  • Operate the mass spectrometer in TURBOIONSPRAY® positive multiple reaction monitoring mode. Use data from calibration standards curve samples and generate a quadratic fit calibration curve for each analyte using the AnalystTM software. Use the standard curve generated to calculate the analyte concentrations for the study samples.
  • Example 1A inhibits the production of kynurenine and N-formyl-kynurenine in IDOl expressing cancer cells in vivo. Specifically, Example 1A dosed at 75 mg/kg, 25 mg/kg and 5 mg/kg resulted in 79%, 59% and 37% inhibition respectively 12 hours after dosing.
  • NSCLC cell line L55, in RPMI 1640 medium supplemented with 10% fetal bovine serum.
  • Initiate the growth of subcutaneous tumors by injecting 5 x 10 6 in a 1:1 mixture of HBSS and MATRIGEL® (BD Biosciences, Franklin Lakes, NJ) in the rear flank of NOD.Cg -Prkdc scid Il2rg tm1Wjl /SzJ mice more commonly known as NOD scid gamma chain knockout mice (NSG) mice (The Jackson Laboratory, Bar Harbour, Maine), which lack T cells, B cells, NK cells, and are deficient in cytokine signaling.
  • NSG NOD scid gamma chain knockout mice
  • V tumor volume
  • L larger measured diameter
  • W smaller of the perpendicular diameter.
  • Example 1A and LY3300054 alone, or in combination by measuring tumor volume by three dimensional caliper measurements twice a week during the course of the study. Measure body weight twice weekly during the course of the study, as a general indicator of tolerability.
  • Example 1A and LY3300054 Formulate Example 1A on a weekly basis in 1% HEC/0.25% Tween 80/0.05% Antifoam and store at 4 °C. Solublize LY3300054 in phosphate buffered saline and store at 4 °C
  • Control group(s) For single agent efficacy studies, administer vehicle for Example 1A alone. For combination studies, administer both vehicles used for Example 1A and LY3300054 according to the same schedule for each compound, respectively. For monotherapy groups in combination efficacy studies, treat the animals with the desired compound and the vehicle for the compound not being dosed following the schedule for the non-dosed compound.
  • Example 1A Treatment with 10, 50, and 100 mg/kg of Example 1A resulted in a dose-responsive effect on tumor growth with only 50 and 100 mg/kg doses showing statistically (p ⁇ .001) relevant growth inhibition at day 20.
  • Body weight loss was measured as the percent change from mean body weights recorded on baseline 6 days after tumor implant for each group.
  • mice showed 5.5% reduction in body weight compared to baseline with the 10, 50, and 100 mg/kg dosed groups showing a 2.5%, 8%, and 2.5% reduction, respectively. While there was a dose-dependent trend in body weight loss with regard to dose, they were not statistically different from vehicle-treated mice.
  • the L55 NCLC human cancer cell line is intrinsically resistant to the allo-response associated with the injection of hPBMCs.
  • the goal of these studies is to assess the ability of compounds to potentiate the allo response allowing human T cells to target and restrict the growth of a human L55 tumors in a mouse that lacks an adaptive immune system (NSG mice).
  • IgG-EN IgG-effector null
  • the statistical analysis of the tumor volume data begins with a data transformation to a log scale to equalize variance across time and treatment groups.
  • the log volume data are analyzed with a two-way repeated measures analysis of variance by time and treatment using the MIXED procedures in SAS software (Version 9.3).
  • the correlation model for the repeated measures is Spatial Power.
  • Treated groups are compared to the control group at each time point.
  • the MIXED procedure is also used separately for each treatment group to calculate adjusted means and standard errors at each time point. Both analyses account for the autocorrelation within each animal and the loss of data that occurs when animals with large tumors are removed from the study early.
  • the adjusted means and standard errors are plotted for each treatment group versus time.
  • the compounds of the present invention are preferably formulated as pharmaceutical compositions administered by a variety of routes. Most preferably, such compositions are for oral or intravenous administration. Such pharmaceutical compositions and processes for preparing same are well known in the art. See, e.g., REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (D. Troy, et al., eds., 21st ed., Lippincott Williams & Wilkins, 2005 ).
  • the term "effective amount” refers to the amount or dose of compound of the invention, or a pharmaceutically acceptable salt thereof which, upon single or multiple dose administration to the patient, provides the desired effect in the patient under diagnosis or treatment.
  • an effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of known techniques and by observing results obtained under analogous circumstances.
  • determining the effective amount for a patient a number of factors are considered by the attending diagnostician, including, but not limited to: the species of mammal; its size, age, and general health; the specific disease or disorder involved; the degree of or involvement or the severity of the disease or disorder; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
  • the compounds of the present invention are generally effective over a wide dosage range.
  • dosages per day normally fall within the daily range of about 0.05-1000 mg.
  • such doses fall within the daily range of 0.1-500 mg.
  • More preferably such doses fall within the daily range of 1-200 mg.
  • dosage levels below the lower limit of the aforesaid ranges may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way.
  • the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP17728990.7A 2016-06-10 2017-05-31 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer Active EP3468965B1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MEP-2020-98A ME03744B (me) 2016-06-10 2017-05-31 Spojevi 1-tetrahidropiranilkarbonil-2,3- dihidro-1h-indola, namijenjeni liječenju raka
SI201730252T SI3468965T1 (sl) 2016-06-10 2017-05-31 Spojine 1-tetrahidropiranilkarbonil-2,3-dihidro-1H-indola za zdravljenje raka
PL17728990T PL3468965T3 (pl) 2016-06-10 2017-05-31 Związki 1-tetrahydropiranylokarbonylo-2,3-dihydro-1h-indolowe do leczenia nowotworu
RS20200623A RS60322B1 (sr) 2016-06-10 2017-05-31 Jedinjenja 1-tetrahidropiranilkarbonil-2,3-dihidro-1h-indola za lečenje kancera
HRP20200769TT HRP20200769T1 (hr) 2016-06-10 2020-05-12 Spojevi 1-tetrahidropiranilkarbonil-2,3-dihidro-1h-indola, namijenjeni liječenju raka

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662348457P 2016-06-10 2016-06-10
PCT/US2017/035097 WO2017213919A1 (en) 2016-06-10 2017-05-31 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer

Publications (2)

Publication Number Publication Date
EP3468965A1 EP3468965A1 (en) 2019-04-17
EP3468965B1 true EP3468965B1 (en) 2020-04-29

Family

ID=59031409

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17728990.7A Active EP3468965B1 (en) 2016-06-10 2017-05-31 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer

Country Status (40)

Country Link
US (2) US9872853B2 (zh)
EP (1) EP3468965B1 (zh)
JP (1) JP6632746B2 (zh)
KR (1) KR102241258B1 (zh)
CN (1) CN109641881B (zh)
AR (1) AR108586A1 (zh)
AU (1) AU2017277833B2 (zh)
BR (1) BR112018072872A2 (zh)
CA (1) CA3027035C (zh)
CL (1) CL2018003543A1 (zh)
CO (1) CO2018013251A2 (zh)
CR (1) CR20180579A (zh)
CY (1) CY1123660T1 (zh)
DK (1) DK3468965T3 (zh)
DO (1) DOP2018000278A (zh)
EA (1) EA037419B1 (zh)
EC (1) ECSP19001734A (zh)
ES (1) ES2797981T3 (zh)
HR (1) HRP20200769T1 (zh)
HU (1) HUE050155T2 (zh)
IL (1) IL263497B (zh)
JO (1) JOP20170131B1 (zh)
LT (1) LT3468965T (zh)
MA (1) MA45224B1 (zh)
MD (1) MD3468965T2 (zh)
ME (1) ME03744B (zh)
MX (1) MX2018015275A (zh)
MY (1) MY197462A (zh)
NZ (1) NZ748500A (zh)
PE (1) PE20190378A1 (zh)
PH (1) PH12018502572A1 (zh)
PL (1) PL3468965T3 (zh)
PT (1) PT3468965T (zh)
RS (1) RS60322B1 (zh)
SG (1) SG11201809625RA (zh)
SI (1) SI3468965T1 (zh)
TW (1) TWI671294B (zh)
UA (1) UA122526C2 (zh)
WO (1) WO2017213919A1 (zh)
ZA (1) ZA201807688B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
BR112018067964B1 (pt) 2016-03-07 2024-01-16 Enanta Pharmaceuticals, Inc Composto, composição farmacêutica que o compreende e uso do referido composto
IL272941B2 (en) 2017-08-28 2023-03-01 Enanta Pharm Inc Antiviral agents for viral hepatitis b
EP3703692A4 (en) * 2017-11-01 2021-04-28 Merck Sharp & Dohme Corp. NEW SUBSTITUTED TETRAHYDROQUINOLINE COMPOUNDS USED AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
US20210002371A1 (en) * 2017-12-21 2021-01-07 Brian A. Sherer Combination of an anti-pd-l1 antibody and ido1 inhibitor for the treatment of cancer
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
EP3836928B1 (en) * 2018-08-17 2024-02-14 Merck Sharp & Dohme LLC Novel substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors
BR112021005091A2 (pt) 2018-09-21 2021-06-08 Enanta Pharmaceuticals, Inc. heterociclos funcionalizados como agentes antivirais
US12065438B2 (en) 2018-11-06 2024-08-20 Merck Sharp & Dohme Llc Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors
CN113271946A (zh) 2018-11-21 2021-08-17 英安塔制药有限公司 官能化杂环化合物作为抗病毒剂
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CN114105961B (zh) * 2021-12-10 2023-09-12 海南梵圣生物科技有限公司 一种ido1抑制剂(ly-3381916)制备方法
CN114213310B (zh) * 2021-12-31 2024-02-23 中国药科大学 吲哚啉化合物及其衍生物、制备方法、药物组合物和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4629657B2 (ja) * 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
ME02461B (me) * 2005-05-10 2017-02-20 Incyte Holdings Corp Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
US7622495B2 (en) * 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
KR20100124272A (ko) * 2008-02-07 2010-11-26 아보트 러보러터리즈 양성 알로스테릭 조절제로서의 아미드 유도체 및 이의 사용방법
MY171866A (en) * 2008-07-08 2019-11-05 Incyte Holdings Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
NO2694640T3 (zh) * 2011-04-15 2018-03-17
ES2733546T3 (es) * 2013-03-15 2019-11-29 Bristol Myers Squibb Co Inhibidores de IDO
WO2015150097A1 (en) * 2014-04-04 2015-10-08 Iomet Pharma Ltd Indole derivatives for use in medicine
UY36391A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
US11135221B2 (en) * 2015-12-23 2021-10-05 Moonshot Pharma Llc Methods for inducing an immune response

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
DOP2018000278A (es) 2018-12-31
EP3468965A1 (en) 2019-04-17
PL3468965T3 (pl) 2020-09-21
EA037419B1 (ru) 2021-03-25
LT3468965T (lt) 2020-06-10
MD3468965T2 (ro) 2020-08-31
UA122526C2 (uk) 2020-11-25
RS60322B1 (sr) 2020-07-31
KR102241258B1 (ko) 2021-04-16
MA45224B1 (fr) 2020-06-30
JP2019518027A (ja) 2019-06-27
HRP20200769T1 (hr) 2020-07-24
CN109641881A (zh) 2019-04-16
JOP20170131B1 (ar) 2021-08-17
DK3468965T3 (da) 2020-06-15
US20170354641A1 (en) 2017-12-14
PE20190378A1 (es) 2019-03-08
CA3027035C (en) 2021-05-04
CL2018003543A1 (es) 2019-03-22
JP6632746B2 (ja) 2020-01-22
ME03744B (me) 2021-04-20
WO2017213919A1 (en) 2017-12-14
PT3468965T (pt) 2020-07-16
ES2797981T3 (es) 2020-12-04
HUE050155T2 (hu) 2020-12-28
TW201806948A (zh) 2018-03-01
CN109641881B (zh) 2022-01-07
MX2018015275A (es) 2019-04-11
TWI671294B (zh) 2019-09-11
MY197462A (en) 2023-06-19
SG11201809625RA (en) 2018-11-29
ECSP19001734A (es) 2019-01-31
CA3027035A1 (en) 2017-12-14
AR108586A1 (es) 2018-09-05
NZ748500A (en) 2020-04-24
US9872853B2 (en) 2018-01-23
US20190161477A1 (en) 2019-05-30
PH12018502572A1 (en) 2019-10-28
IL263497A (en) 2019-01-31
KR20190003750A (ko) 2019-01-09
US10759786B2 (en) 2020-09-01
ZA201807688B (en) 2020-08-26
AU2017277833A1 (en) 2018-11-15
CR20180579A (es) 2019-02-08
EA201892479A1 (ru) 2019-07-31
BR112018072872A2 (pt) 2019-03-06
SI3468965T1 (sl) 2020-07-31
CO2018013251A2 (es) 2019-01-18
IL263497B (en) 2020-11-30
AU2017277833B2 (en) 2020-07-02
CY1123660T1 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
EP3468965B1 (en) 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer
JP7042812B2 (ja) トリアゾロピリミジン化合物の結晶形態
AU2024200013A1 (en) Prodrug modulators of the integrated stress pathway
JP2022532247A (ja) Ｃｂｌ－ｂ阻害のためのシアノシクロブチル化合物及びその使用
JP2021514982A (ja) インドール−２−カルボニル化合物及びｂ型肝炎治療のためのそれらの使用
US20210317079A1 (en) Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
WO2020224652A1 (zh) 一类泛素化特异性蛋白酶抑制剂及其制备方法与应用
CA3166135A1 (en) The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer
US10501466B2 (en) WDR5 inhibitors and modulators
IL267829A (en) New Amino-Imidazopyridine History as Janus Kinase Inhibitors and Their Pharmacological Use
JP2021525810A (ja) トリプトファン異化のモジュレーター
CN117881657A (zh) 苯基-氨磺酰基-苯甲酸衍生物作为erap1调节剂
JP6941630B2 (ja) 抗菌剤としての（ｒ）−４（５−（シクロプロピルエチニル）イソオキサゾール−３−イル）−ｎ−ヒドロキシ−２−メチル−２−（メチルスルホニル）ブタンアミドの結晶形
TWI829329B (zh) 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑
RU2811733C1 (ru) Противоопухолевая комбинация хидамида и целекоксиба
US20240270736A1 (en) Macrocyclic heterocycles and uses thereof
CN108349882B (zh) 一种取代的丙烯酰胺化合物及其药物组合物
KR20230072446A (ko) 암의 치료를 위한 인돌아민 2,3-디옥시게나아제 저해제와 면역체크포인트 억제제의 상승적 조합
EP4423075A1 (en) Ccr6 receptor modulators
IL296700A (en) Process, preparations and crystalline forms of substituted pyridinone-pyridinyl compounds
CA3235910A1 (en) Ccr6 receptor modulators
TW202416950A (zh) 雜芳基甲醯胺及相關gpr84拮抗劑及其用途

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190110

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20191105

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1262631

Country of ref document: HK

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

INTC Intention to grant announced (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

INTG Intention to grant announced

Effective date: 20200318

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20200769T

Country of ref document: HR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017015750

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1263115

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20200610

REG Reference to a national code

Ref country code: MA

Ref legal event code: VAGR

Ref document number: 45224

Country of ref document: MA

Kind code of ref document: B1

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20200769T

Country of ref document: HR

Payment date: 20200512

Year of fee payment: 4

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3468965

Country of ref document: PT

Date of ref document: 20200716

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20200710

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20200401516

Country of ref document: GR

Effective date: 20200716

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20200769

Country of ref document: HR

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: MD

Ref legal event code: VAGR

Ref document number: 3468965

Country of ref document: MD

Date of ref document: 20200831

Kind code of ref document: T2

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E019453

Country of ref document: EE

Effective date: 20200702

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20200429

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 34766

Country of ref document: SK

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MD

Payment date: 20200730

Year of fee payment: 4

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2797981

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20201204

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E050155

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200429

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017015750

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20210201

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MA

Payment date: 20200529

Year of fee payment: 4

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20200769

Country of ref document: HR

Payment date: 20210430

Year of fee payment: 5

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MD

Payment date: 20210531

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20220420

Year of fee payment: 6

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20200769

Country of ref document: HR

Payment date: 20220527

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20220422

Year of fee payment: 6

Ref country code: SE

Payment date: 20220420

Year of fee payment: 6

Ref country code: RS

Payment date: 20220512

Year of fee payment: 6

Ref country code: RO

Payment date: 20220502

Year of fee payment: 6

Ref country code: PT

Payment date: 20220426

Year of fee payment: 6

Ref country code: NO

Payment date: 20220422

Year of fee payment: 6

Ref country code: MC

Payment date: 20220422

Year of fee payment: 6

Ref country code: LU

Payment date: 20220420

Year of fee payment: 6

Ref country code: LT

Payment date: 20220420

Year of fee payment: 6

Ref country code: IT

Payment date: 20220421

Year of fee payment: 6

Ref country code: IE

Payment date: 20220421

Year of fee payment: 6

Ref country code: HU

Payment date: 20220426

Year of fee payment: 6

Ref country code: HR

Payment date: 20220527

Year of fee payment: 6

Ref country code: GB

Payment date: 20220425

Year of fee payment: 6

Ref country code: FR

Payment date: 20220421

Year of fee payment: 6

Ref country code: ES

Payment date: 20220601

Year of fee payment: 6

Ref country code: EE

Payment date: 20220422

Year of fee payment: 6

Ref country code: DK

Payment date: 20220429

Year of fee payment: 6

Ref country code: DE

Payment date: 20220420

Year of fee payment: 6

Ref country code: CZ

Payment date: 20220427

Year of fee payment: 6

Ref country code: CY

Payment date: 20220421

Year of fee payment: 6

Ref country code: BG

Payment date: 20220505

Year of fee payment: 6

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MD

Payment date: 20220524

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20220426

Year of fee payment: 6

Ref country code: SI

Payment date: 20220505

Year of fee payment: 6

Ref country code: PL

Payment date: 20220421

Year of fee payment: 6

Ref country code: LV

Payment date: 20220420

Year of fee payment: 6

Ref country code: GR

Payment date: 20220421

Year of fee payment: 6

Ref country code: FI

Payment date: 20220414

Year of fee payment: 6

Ref country code: CH

Payment date: 20220420

Year of fee payment: 6

Ref country code: BE

Payment date: 20220420

Year of fee payment: 6

Ref country code: AT

Payment date: 20220421

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20220422

Year of fee payment: 6

Ref country code: IS

Payment date: 20220419

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20220531

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20220421

Year of fee payment: 6

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1263115

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200429

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602017015750

Country of ref document: DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20200769

Country of ref document: HR

Effective date: 20230531

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E019453

Country of ref document: EE

Effective date: 20230531

REG Reference to a national code

Ref country code: NO

Ref legal event code: MMEP

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20230531

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20230531

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20230601

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 34766

Country of ref document: SK

Effective date: 20230531

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 1263115

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231208

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20230531

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20230531

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230601

Ref country code: RS

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231130

Ref country code: NO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230601

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231208

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230601

REG Reference to a national code

Ref country code: MD

Ref legal event code: KA4A

Ref document number: 3468965

Country of ref document: MD

Kind code of ref document: T2

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20240223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231201

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MD

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230601

Ref country code: HR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20240703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230601